title: Acute and severe acne in a patient treated with bevacizumab.
abstract: BACKGROUND
  Bevacizumab is a recombinant, humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that inhibits angiogenesis. Bevacizumab is typically well tolerated; its major side effects include hypertension, proteinuria, bleeding, gastrointestinal perforation, and arterial thrombotic events, among others. Cutaneous side effects associated with the use of bevacizumab are rare and involve mainly itching and exfoliative dermatitis. Nonspecific skin rash and acneiform eruptions have recently been described in patients following infusion of bevacizumab.
  
  
  METHODS
  Findings in a 52-year-old patient with stage IV lung cancer with brain metastasis, who developed severe, acute, and persistent acne after intravenous (IV) infusion of bevacizumab, are examined.
  
  
  RESULTS
  The cutaneous eruption was classified as true acne rather than as an acneiform eruption because all cutaneous lesions of acne, namely comedones, inflammatory papules, and pustules, were present.
  
  
  CONCLUSIONS
  To the authors' knowledge, this is the first report of an association between acne and IV administration of bevacizumab.
authors: Departments of Dermatology Oncology, Jiménez Díaz Foundation, Autonomous University of Madrid, Madrid, Spain. anamaria.molinaruiz@gmail.com
authors: Ana María
authors: AM
authors: Molina-Ruiz
authors: Manuel
authors: M
authors: Domine
authors: Luis
authors: L
authors: Requena
mesh_terms: D000152:Acne Vulgaris / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D000208:Acute Disease; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab